Comparison of the ocular surface microbiota in meibomian gland dysfunction patients and healthy subjects

• Conditions: meibum; Meibomian gland dysfunction patients; Meimobian gland dysfunction (MGD); blepharitis; ocular microbiota; bacteria; 16S rDNA

• Registration Number: TCTR20210221002
• Lead Sponsor: Rachadapiseksompoch fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-21
• Study Completion: 2021-11-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

MGD patients
1)Adult patients aged 18-80 years with a chief complaint of one of the following symptoms: dryness, foreign body sensation, burning, or tearing.
2)A diagnosis of MGD with two or more of the following signs : redness or thickening of the lid margin, telangiectasia, reduced or no secretions, poor quality secretions, and gland obstruction.
3)If both eyes are involved, the investigator (U.R.) will randomly select only one eye.
Healthy controls
1)No chief complaint of any dry eye symptoms or tear break up time (TBUT) is equal to or longer than 5 seconds without obvious dry eye symptoms.
2)MG associated assessments do not meet the criteria for diagnosis of MGD.
3)Corneal staining is negative
4)If both eyes are involved, the investigator (U.R.) will randomly select only one eye.

Exclusion Criteria

Both MGD patients and Healthy controls
1)Use topical or systemic antibiotics within the past month
2)Use other topical eye drops within 3 months (other than artificial tears)
3)Use contact lenses within the past month
4)Active allergies, infections, or inflammatory diseases of the ocular surface unrelated to dry eye or MGD
5)A history of ocular trauma or surgery within one year
6)Has systemic diseases affecting the ocular surface
7)Healthcare workers

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
bacterial identification in MGD patients and healthy controls cross section 16s rRNA sequencing

Secondary Outcome Measures

Name	Time	Method
Tear cytokines level in MGD patients and healthy controls Cross section Luminex using a cytokine kit